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Introduction {#sec1}
============

Aging is a major risk factor for many diseases and mortality ([@bib68]). Thus, targeting the aging process directly by pharmacological means could be a viable strategy to promote a healthier and longer life ([@bib58]). Efforts are underway to explore these possibilities and to identify aging-preventive compounds, so-called "geroprotectors." However, the list of candidates that are thought to confer such health and lifespan benefits to humans has remained very small ([@bib6], [@bib51]). Even though screens covering tens of thousands of bio-active molecules have identified many drugs that extend the lifespan in simple model organisms ([@bib59], [@bib73], [@bib112]), validating their potential efficacy in humans is extremely time-consuming, limited in throughput, and restricted by ethical considerations. Thus, the sheer candidate numbers from such screens and their expected high frequency of a non-conserved effect in humans have discouraged their further evaluation ([@bib51]).

So far, two major strategies have been tried to increase the probability of identifying compounds that are effective in humans. One approach has been to screen for them in mammalian laboratory models (e.g., mice, rats, or primates) but such studies are limited by significant costs, duration, and ethical considerations. The other approach has been to devise screening methodologies directly in humans that do not require treatment of individuals but limit themselves to compound screening in human cell culture models and the computational interpretation of the resulting data. This latter approach has been proven to be feasible, at least to identify dietary restriction mimetics ([@bib11]).

Here we try to take such cell culture- and computation-based approaches to a higher level of sophistication. Recent studies have demonstrated the power of human transcriptomes for biological age prediction ([@bib72], [@bib88], [@bib111]). We make use of this predictive power by creating age classifiers from age-stratified human tissue transcriptomes (from the Genotype-Tissue Expression \[GTEx\] Consortium; [@bib29], [@bib30]). We then use these classifiers to evaluate transcriptomic changes induced by 1,309 unique compounds in human cells (from the Connectivity Map \[CMap\]; [@bib52]) to identify geroprotectors. This results in numerous candidates, which we validate in the model organism *Caenorhabditis elegans.* Eventually, we focus on two of our top hits, the Hsp90 inhibitors monorden and tanespimycin. We show that they promote lifespan extension and better health, presumably through a mechanism that activates the transcription factor HSF1 and leads to improved protein homeostasis. Finally, we place our findings in the context of recent work that describes Hsp90 inhibitors as immuno-suppressants ([@bib103]) and senolytics ([@bib26]). Both of these functions are absent in *C. elegans* but should further potentiate the geroprotective benefits of Hsp90 inhibition when applied to humans.

Results {#sec2}
=======

Construction of a Core Set of Transcriptome-Based Age Classifiers {#sec2.1}
-----------------------------------------------------------------

Recent studies have demonstrated that biological age can be estimated by machine learning approaches applied to healthy tissue transcriptome datasets ([@bib72], [@bib88]). We reasoned that applying such biological age classifiers to drug-induced transcriptomes may reveal compounds with youth-inducing properties ([Figure 1](#fig1){ref-type="fig"}A). To test this, we turned to data available from the GTEx Consortium that contained a diverse set of human tissue transcriptomes originating from donors of various ages and both genders ([@bib29], [@bib30], [@bib111]). GTEx transcriptomes were downloaded and preprocessed as described previously ([@bib30], [@bib63], [@bib95]), resulting in a dataset of 8,555 transcriptomes from 51 tissues from both genders grouped into decade-sized age bins (ages 20--29, 30--39, 40--49, 50--59, and 60--69) ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Study Strategy and Generation of Transcriptome-Based Age Classifiers(A) General strategy for the discovery of geroprotective drugs. Transcriptomes of young versus old individuals (step 1) are used to generate age classifiers (step 2). These classifiers are then applied to drug response transcriptomes (step 3) to identify compounds that change the transcriptome to a more youthful state. A ranking is generated, prioritizing compounds that are most likely to be geroprotective (step 4). Finally, we assess the highest-ranked compounds against known geroprotectors to estimate the efficacy of our prioritization method (step 5).(B) The age and gender demographics of the GTEx data used in this study.(C) Clustering of the differential gene expression data for a representative binary young (50--59) versus old (60--69) comparison performed in a particular tissue (coronary artery from females). Lines represent transcripts, and columns represent the individual tissue donors. Only transcripts used in the respective classification model are shown.(D and E) Inclusion criteria for the final classification models, demanding sensitivity (D), specificity (D), and accuracy (E) scores of above 0.75.(F) Distribution of the final 24 models among tissues, age bins, and genders. The letters M and F refer to the gender from which the model was generated (male and female, respectively). A number (20, 30, 40, or 50) denotes the young age decade from which the model was generated (either 20--29, 30--39, 40--49, or 50--59; these decades were always compared with the old decade of 60--69 years). The tissue names follow the GTEx naming scheme.

Next we took a binary classification approach to train machine learning models to distinguish "young" versus "old" ages. The transcriptomic data were separated by tissue and gender and kept in the decade-sized age bins. We defined being old as the decade of 60--69 years (the oldest decade in the GTEx data that matched our minimum sample number criteria) and, for each gender and tissue, made binary comparisons of this old age bin with any of the corresponding younger age bins. To minimize noise and limit the analysis to transcripts most likely to distinguish old from young samples, we filtered the datasets as follows. Of all possible binary comparisons, only those were made that contained at least 10 transcriptomes in each of the young and old datasets. The lowest 10% abundant transcripts were removed from the datasets. We further limited the analysis to genes that were differentially expressed between the two compared age bins. Finally, we filtered to only include genes present in the CMap data ([@bib52]). [Figure 1](#fig1){ref-type="fig"}C provides an example of a tissue taken from females (coronary artery) and pairwise age comparison (here, age bins 50--59 versus 60--69 years) that has undergone this processing, showing clustering of the resulting differential gene expression data. Using these filtered datasets, we generated random forest models and tuned them in an automated systematic manner ([@bib50], [@bib55]; [Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}), resulting in 182 age classification models of variable quality ([Figure 1](#fig1){ref-type="fig"}; [Table S1](#mmc2){ref-type="supplementary-material"}). To generate a final core set of models, we then applied cutoff criteria based on model sensitivity, specificity, and accuracy from the training and testing phases ([Figures 1](#fig1){ref-type="fig"}D and 1E), ensuring that only the most effective classifiers remained. This resulted in 24 final models ([Figure 1](#fig1){ref-type="fig"}F; [Table S2](#mmc3){ref-type="supplementary-material"}). These 24 models were comprised of 1,927 unique transcripts, most of which were unique to individual models ([Table S2](#mmc3){ref-type="supplementary-material"}). Although the majority of these transcripts had no known age-related functions, several prominent aging-related genes were present in this list and contributed to the age classification, including glutathione S-transferase pi 1 (GSTP1; [@bib1], [@bib64], [@bib104]), insulin-like growth factor 1 receptor (IGF1R; [@bib42], [@bib49], [@bib96])), the sirtuin SIRT1 ([@bib15], [@bib40], [@bib46], [@bib80], [@bib98]), and mitochondrial uncoupling protein 2 (UCP2; [@bib17], [@bib25])). A full list of the 1,927 genes and to which tissue models they contribute is provided in [Table S2](#mmc3){ref-type="supplementary-material"}.

Application of the Age Classifiers to Rank Compounds by Their Geroprotective Potential {#sec2.2}
--------------------------------------------------------------------------------------

Next we applied these 24 age classification models to detect geroprotective compounds ([Figure 1](#fig1){ref-type="fig"}A, steps 3--5). We turned to the publicly available CMap, a resource consisting of over 6,000 transcriptomes of various compound treatments performed on a selection of human cell lines ([@bib52]). In total, 1,309 different compounds are covered by this dataset, including Food and Drug Administration (FDA)-approved medications but also a variety of other bioactive molecules. CMap has successfully been used to find drugs affecting complex phenotypes; e.g., celastrol for the treatment of diabetes ([@bib57]) and allantoin, which acts as a caloric restriction mimetic ([@bib11]).

We reasoned that a cell line's exposure to aging-preventive compounds would induce transcriptional changes classified as young by our models ([Figure 1](#fig1){ref-type="fig"}A). Before we could apply our models to the CMap data, we first had to take into account that the CMap data and our GTEx-derived models originate from different types of cells with distinct baseline gene expression profiles. Thus, for each age classification model, we generated a prototypical "middle age" transcriptome comprised of each gene's average expression level between the young and old age group of the GTEx data used to generate the model ([STAR Methods](#sec4){ref-type="sec"}). This resulted in transcriptomes that the models should not easily classify as either young or old ([Figure 2](#fig2){ref-type="fig"}A). Next we applied the fold gene expression changes of the drug responses in CMap to these prototypical middle age transcriptomes and asked our models whether this would shift the middle age transcriptome toward a young classification and, hence, a more youthful state. In this way, each CMap perturbation entry was systematically applied to all of the 24 models' specific middle age transcriptomes ([Figure 2](#fig2){ref-type="fig"}A), resulting in 24 different predictions for each of CMap's more than 6,000 entries ([Table S2](#mmc3){ref-type="supplementary-material"}). Because many of the 1,309 compounds in the CMap often have been evaluated at various doses and incubation times or in different cell lines, and to give a drug the greatest possibility to show its geroprotective potential, we selected, for each drug, the CMap entry that gave the maximal probability of being young. This consolidated the dataset to 24 different predictions each for CMap's 1,309 compounds. Furthermore, for better comparability between predictions from different models, we normalized model results to a maximal amplitude of 0.5, centered these probabilities around 0, and thereby created a "geroprotective index" in which a positive value signified prediction of a rejuvenated transcriptome ([Figure 2](#fig2){ref-type="fig"}B; [Table S3](#mmc4){ref-type="supplementary-material"}).Figure 2Drugs Ranked by Geroprotective Index(A) Pipeline for ranking CMap compounds by their geroprotective index. Tissues are separated into young and old groups used to build models. Middle age-representative transcriptomes are generated by averaging young and old. CMap drug response fold changes are applied to the middle age transcriptomes to generate "drug-induced" transcriptomes for each candidate drug. Age-classifying models predict the ages of the drug-induced transcriptomes. Enrichment scores are generated based on the 24 models' separate predictions to find drugs most often ranked as geroprotective.(B) Geroprotective index ranking of CMap compounds for each of the 24 models (distribution of scores). The geroprotective index is a model's prediction (the probability) of whether a transcriptome should be classified as young (see [STAR Methods](#sec4){ref-type="sec"} for details).(C) Consolidated geroprotective index scores (from B) of the CMap compounds (distribution, black line). The red line designates the mean absolute deviation, used as significance cutoff.(D) Overlap between our significant geroprotector candidates (31 total) and any CMap compounds that are listed as lifespan-extending in the DrugAge database (51 total) (p value generated by Fisher's exact test).(E) The top 15 geroprotective candidate compounds resulting from our method. Compounds published to increase the lifespan in either mice (m), flies (f), or worms (w) are indicated.

To obtain a final evaluation for each drug, we assessed how often a drug was ranked as geroprotective by the 24 models. Although this approach may omit drugs with highly tissue-specific geroprotective effects, it prioritizes compounds that provide benefits across many tissues and, thus, might be particularly suitable for whole-organism treatment. We first consolidated the predictions from the 24 different models into one distribution and determined the mean absolute deviation ([Figure 2](#fig2){ref-type="fig"}C, red line) to establish a significance cutoff for our predictions. Then we counted how often a drug was predicted by one of the 24 models to have a geroprotective index above this cutoff and performed enrichment tests in relation to the whole distribution of predictions. After correcting for multiple-hypothesis testing, this resulted in a final significance-based ranking of drugs for their geroprotective potential ([Table S3](#mmc4){ref-type="supplementary-material"}). We selected a corrected p value cutoff of 0.05 to form a candidate list of drugs for further consideration, which consisted of 31 compounds in total ([Table S3](#mmc4){ref-type="supplementary-material"}; [Figure 2](#fig2){ref-type="fig"}E shows the top 15 compounds). To assess the efficacy of our method, we explored what was known about these 31 top candidates. Turning to DrugAge ([@bib5]), a database of compounds yielding lifespan effects in various model organisms, we found that, of its over 400 unique drugs that significantly increase the lifespan and, thus, are considered geroprotectors, 51 were present in CMap, and of these, 8 were in common with our list of 31 top candidates. This showed that our top candidates were significantly enriched for known geroprotective compounds (p \< 0.01) ([Figure 2](#fig2){ref-type="fig"}D; [Table S3](#mmc4){ref-type="supplementary-material"}), confirming that our screening method worked well.

[Figure 2](#fig2){ref-type="fig"}E shows the top 15 compounds from our candidate list, covering a wide range of mechanistic targets. These compounds include valproic acid and trichostatin A, two histone deacetylase (HDAC) inhibitors shown previously to increase the lifespan in worms ([@bib11], [@bib23]) and flies ([@bib94]); the phosphatidylinositol 3-kinase (PI3K) inhibitors LY-294002 and wortmannin, shown to increase the lifespan in worms ([@bib11]) and flies ([@bib18], [@bib66]); estradiol, shown to increase the lifespan in worms ([@bib112]); the target of rapamycin (TOR) inhibitor rapamycin (also known as sirolimus), shown to extend the lifespan in worms ([@bib11]), flies ([@bib8]), and mice ([@bib37]); and genistein, an angiogenesis inhibitor, shown to extend the lifespan in worms ([@bib53]). Also several antidepressants were among our candidates, a class of drugs that has been shown previously to influence lifespan ([@bib73], [@bib113]). Finally, in ranks 16 to 31, we found several drugs that have been suggested to protect from all-cause mortality in epidemiological studies in humans: the diabetes therapeutic agent metformin ([@bib4]), the rheumatoid arthritis therapeutic agent methotrexate ([@bib105]), acetylsalicylic acid (aspirin) ([@bib32]), as well as clozapine, a drug used to treat serious mental illness ([@bib38]).

Taken together, our screening approach was able to successfully rank compounds by their geroprotective potential, revealing a top candidate list significantly enriched for known lifespan-extending compounds. In addition, some previously undocumented geroprotector candidates were identified that should be interesting to investigate further.

For the scientific community, we provide an easy-to-use R script that is based on our classifiers and can be applied to make geroprotective predictions from any drug-induced transcriptomic changes in human cells ([Figure S2](#mmc1){ref-type="supplementary-material"}; see [STAR Methods](#sec4){ref-type="sec"} for the download link).

Validation of Geroprotector Candidates via *C. elegans* {#sec2.3}
-------------------------------------------------------

To test for lifespan-extending capabilities among our candidate compounds, we turned to the nematode *C. elegans*, a relatively short-lived model organism frequently used in aging research, including drug screening for geroprotectors ([@bib11], [@bib12], [@bib112]). We selected 29 compounds for evaluation. These included 14 of the top 15 compounds from our candidate list (p value cutoff, 3.6 × 10^−3^; [Figure 2](#fig2){ref-type="fig"}E); tanespimycin was initially omitted because of target redundancy with monorden and exceptional cost, but retested subsequently \[see below\]). Additionally, we included 15 compounds that we selected by hand ([Table S3](#mmc4){ref-type="supplementary-material"}), irrespective of their ranking, either because we considered them promising geroprotector candidates based on existing annotations or to include drugs ranked poorly by our predictors (negative controls).

Compounds were evaluated at 50 μM (see [Table S4](#mmc5){ref-type="supplementary-material"} for solvents), a concentration that was deemed to be optimal in light of previously conducted *C. elegans*-based geroprotector screens ([@bib11], [@bib12], [@bib112]). To obtain high-resolution lifespan data on this substantial panel of drugs, we used an automated imaging and analysis platform called the *C. elegans* "lifespan machine" ([@bib90]), which has repeatedly been proven to be a reliable tool ([@bib56], [@bib62], [@bib91]). We applied the compounds to L4-stage larvae (animals near the end of their development), performed the survival assays, and eventually processed the data, making sure that each drug was tested using at least 50 worms. This resulted in a final list of 25 drugs giving high-quality lifespan data, displaying a range of lifespan phenotypes from an almost 10% decrease to more than a 25% increase ([Figure 3](#fig3){ref-type="fig"}A). Five compounds extended the lifespan significantly and by more than 10%: felbinac (an anti-inflammatory from a class of compounds known to extend worm lifespan; [@bib39]), valproic acid, LY-294002, rapamycin, and monorden ([Figure 3](#fig3){ref-type="fig"}A, highlighted by red circles; [Table S4](#mmc5){ref-type="supplementary-material"}; see [Figures 3](#fig3){ref-type="fig"}B--3D and [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B for individual survival curves; we reproduced all these results by biological replicates). One compound (tyrphostin AG-1478, an epidermal growth factor receptor (EGFR) inhibitor; [@bib24]) that significantly extended the lifespan but did not meet our inclusion criteria for worm numbers in the initial screen, was later validated with larger numbers of worms ([Figure S3](#mmc1){ref-type="supplementary-material"}C; [Table S4](#mmc5){ref-type="supplementary-material"}). Unfortunately, a few lifespan extension phenotypes reported previously by other labs could not be confirmed by our assays (i.e., genistein), but this may be due to different experimental setups and/or dosing.Figure 3Lifespan Screening and Discovery of the Geroprotective Drugs Monorden and Tanespimycin(A) High-resolution lifespan curves were generated (inset), and changes in median lifespan were calculated for each candidate drug relative to the solvent control (bar graph). Compounds that were prioritized by our classification method (blue dots), that were already found to extend lifespan (gray dots), or that significantly extended lifespan in our study (p \< 0.05 \[log rank test\] and \>10% extension, red dots) are indicated.(B) The survival curve of LY-294002-treated worms from (A).(C) The survival curve of rapamycin (sirolimus)-treated worms from (A).(D) The survival curve of monorden-treated worms from (A).(E) The survival curve of monorden-treated worms, generated using the manual scoring method of prodding with a platinum wire.(F) The survival curve of tanespimycin-treated worms.(G) The survival curve of worms grown from the L4 stage on RNAi bacteria targeting *daf-21* (*daf-21* RNAi clone 1), the *C. elegans* gene encoding Hsp90.See [Table S4](#mmc5){ref-type="supplementary-material"} for drug concentrations, worm numbers and statistics, and [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C for additional lifespan curves of compounds significantly increasing lifespan.

Of the 25 tested compounds, the compounds prioritized by our classification models showed, in their mean, a reasonable lifespan extension (6%; [Table S4](#mmc5){ref-type="supplementary-material"}), whereas such an effect was absent from the hand-selected compounds (−0.1%; [Table S4](#mmc5){ref-type="supplementary-material"}). This is a remarkable outcome considering that we tested each compound only at a single dose and administered it only once (at the L4 stage), not optimizing treatment conditions and, thus, risking the occurrence of false negatives. Despite these limitations, we found a significant positive correlation between our ranking from the *in silico* analysis ([Figure 2](#fig2){ref-type="fig"}E; [Table S3](#mmc4){ref-type="supplementary-material"}) and the compounds' ability to extend lifespan in *C. elegans* (p = 0.02; [Figure S3](#mmc1){ref-type="supplementary-material"}D; [Table S5](#mmc6){ref-type="supplementary-material"}). Furthermore, the four compounds that exhibited the largest lifespan extension in our assays---monorden, rapamycin, LY-294002, and valproic acid ([Figure 3](#fig3){ref-type="fig"}A)---were all derived from our transcriptomics-based predictions, underscoring the power of our *in silico* approach to discover previously undocumented potent geroprotective compounds.

Turning back to the actual results of our assays, we conclude that we were able to confirm the well-known geroprotective effects of rapamycin and LY-294002, that we were able to support the lifespan-extending roles of valproic acid (which has recently been suggested to suffer from reproducibility issues; [@bib60]) and tyrphostin AG-1478 ([@bib112]), and that we discovered two previously undocumented geroprotective compounds: felbinac and monorden.

Hsp90 Inhibition Extends the Lifespan of *C. elegans* {#sec2.4}
-----------------------------------------------------

From here on, we decided to focus on monorden (also known as radicicol), which emerged as the most lifespan-extending candidate from our initial assays ([Figure 3](#fig3){ref-type="fig"}A; [Table S4](#mmc5){ref-type="supplementary-material"}). Monorden is an established inhibitor of the chaperone protein Hsp90 ([@bib28]). Hsp90 helps to fold and, thus, assists with the function of many client proteins. Nevertheless, it also can sequester and inhibit proteins and their functions; e.g., the heat shock response transcription factor HSF1. Until now, monorden had remained unknown as a lifespan-extending drug. First, we validated its lifespan benefits by a conventional *C. elegans* lifespan assay using manual poking ([@bib35]). Consistent with our lifespan machine data, we again observed a robust lifespan extension by approximately 25% at 50 μM ([Figure 3](#fig3){ref-type="fig"}E). We note that, in absolute numbers, the lifespans observed by the lifespan machine tended to be shorter than lifespans observed by manual scoring. Reasons could be different light exposure, different humidity, or slight shifts in temperature between the scoring methods. Nonetheless, monorden extended the lifespan in both setups, confirming the robustness of this finding. Because monorden is thought to target Hsp90, we next wanted to confirm that inhibition of this chaperone is indeed the mechanism by which the lifespan phenotypes are conferred. Coincidentally, we had identified tanespimycin (another Hsp90 inhibitor but structurally quite distinct from monorden; [@bib9], [@bib81]) as the third-best geroprotector candidate in our initial *in silico* screen ([Figure 2](#fig2){ref-type="fig"}E), although we had omitted it from initial validation in *C. elegans* because of target redundancy with monorden and the exceptional cost of the compound. Eventually testing the effects of tanespimycin at 25 μM, a lower dose to accommodate the cost of the drug, we likewise observed a substantial increase in lifespan ([Figure 3](#fig3){ref-type="fig"}F; [Table S4](#mmc5){ref-type="supplementary-material"}).

Next we tested whether genetic perturbation of *daf-21,* the gene encoding Hsp90 in *C. elegans*, can lead to lifespan extension too. Prior work suggested that RNAi against *daf-21* starting from various developmental stages impairs growth or shortens the lifespan ([@bib86]). Nevertheless, when we knocked down *daf-21* from the L4 stage, we observed a significant lifespan extension, consistent with the effects observed with monorden or tanespimycin treatment ([Figure 3](#fig3){ref-type="fig"}G; [Table S4](#mmc5){ref-type="supplementary-material"}). To better understand this potential discrepancy between our and prior findings, we determined the lifespan effects of *daf-21 RNAi*, comparing two different RNAi clones (one slightly weaker \[1\] and one stronger \[2\]; we consider clone 2 stronger because it can lead to developmental arrest, similar to a *daf-21* deletion \[[@bib7]\], whereas clone 1 does not), applying them from different stages of development or early adulthood and also testing the effect of diluting these RNAi clones and, thus, lowering their knockdown efficiency. Interestingly, we found that *daf-21* RNAi from early development (L1 or L2 stages) leads to either developmental arrest (when using RNAi clone 2 from L1) or, otherwise, lifespan shortening ([Figure S4](#mmc1){ref-type="supplementary-material"}A), in line with prior work. Similarly, knockdown from day 1 of adulthood shortened the lifespan ([Figure S4](#mmc1){ref-type="supplementary-material"}A). However, specifically *daf-21* RNAi from the L4 stage did not cause lifespan shorting. Instead, it extended the lifespan when using the weaker RNAi clone 1 ([Figure S4](#mmc1){ref-type="supplementary-material"}A; [Figure 3](#fig3){ref-type="fig"}G). Next we tested the effect of diluting either of the *daf-21* RNAi clones in control RNAi and determined their lifespan effect when applied from the L4 stage. We found that lifespan extension phenotypes increased when we diluted the RNAi clones, with lifespan extension by the weaker RNAi clone 1 peaking at a concentration of 25% and the stronger RNAi clone 2 peaking at 10% ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These data argue that the timing of *daf-21* RNAi onset as well as the efficiency of the knockdown strongly affect the resulting lifespan phenotypes and that prior work may have missed a lifespan-extending phenotype from the L4 stage, likely because of stronger knockdown efficiency and/or slight differences in RNAi onset in their experiments.

Eventually, we conducted two more experiments to confirm that inhibitors like monorden or tanespimycin exert their phenotypes through Hsp90 inhibition. First, loss-of-function mutations in *daf-21* can promote Dauer formation ([@bib7]), a developmental arrest state of *C. elegans* that is exceptionally long-lived and resistant to environmental stress. Consistent with monorden inhibiting Hsp90, we found that it enhanced Dauer formation of wild-type animals at 27°C ([Figure S4](#mmc1){ref-type="supplementary-material"}D; [Table S4](#mmc5){ref-type="supplementary-material"}). Second, the lifespan benefits of monorden or tanespimycin should be suppressed by knockdown of *daf-21*. Testing this for monorden, we found that this was indeed the case ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

We conclude that Hsp90 inhibition, as long as it is mild and preferentially conducted from late development onward, extends the lifespan of *C. elegans* and that monorden or tanespimycin treatment from late development onward is a robust pharmacological way to confer it.

Pharmacological Inhibition of Hsp90 Improves the Healthspan of *C. elegans* {#sec2.5}
---------------------------------------------------------------------------

Although living a longer life is tempting, even more importantly, we would like to increase the time in our life that we spend in good health, the so-called healthspan. To test for potential healthspan benefits from monorden treatment, we first turned again to the *C. elegans* lifespan machine. In addition to lifespan data, it also generates information regarding the position of worms throughout time. We reasoned that the degree of correlation of worm positions between successive time points provides information of the worm population's activity level ([Figure S5](#mmc1){ref-type="supplementary-material"}). Using this rather qualitative analysis, we found that monorden-treated worms had an extended period of active life, as did worms treated with the known geroprotectors rapamycin and LY-294002 ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Health Benefits Resulting from Drug Treatments(A) The activity levels of different worm populations were assessed during aging (as described in [Results](#sec2){ref-type="sec"} and [STAR Methods](#sec4){ref-type="sec"} and further illustrated in [Figure S5](#mmc1){ref-type="supplementary-material"}). Differences between activity curves are indicated.(B) Health as assessed by the animals' thrashing frequency. Each dot represents a period of at least 2 s in a 1-min window during which at least 20 worms were followed. ^∗^p \< 0.01 (Wilcoxon Mann Whitney test). Red lines indicate the median and quartiles. See [Table S4](#mmc5){ref-type="supplementary-material"} for worm numbers and statistics.(C) Health as assessed by the animals' maximum velocity in early and mid-life (day 1 and day 4 of adulthood). Each dot represents one worm's maximum velocity during a period of 30 s. ^∗^p \< 0.01 (Wilcoxon Mann Whitney test). Red lines indicate the median and quartiles. See [Table S4](#mmc5){ref-type="supplementary-material"} for worm numbers and statistics.

To validate this monorden-induced healthspan increase, we tested the motility of worms using a "thrashing" assay. This assay measures physical motility based on the swimming movements that *C. elegans* perform in liquid. We applied monorden to L4 worms and evaluated young (day 1 adulthood) and old (day 13 adulthood) animals. Comparing young and old worms, we saw a clear decline of the thrashing rate with age under control as well as treated conditions ([Figure 4](#fig4){ref-type="fig"}B). However, monorden treatment significantly increased the thrashing rate by up to 5% in young and, more importantly, by at least 12% in old worms (p \< 0.05) ([Figure 4](#fig4){ref-type="fig"}B; [Table S4](#mmc5){ref-type="supplementary-material"}).

A second powerful metric of *C. elegans* healthspan is their "maximum velocity." It declines quite rapidly during adulthood, but when measured mid-life, it is predictive of the animals' healthspan and lifespan ([@bib33]). Thus, we applied monorden to L4 animals and measured their maximum velocity during 30-s time frames on day 1 (young) and day 4 of adulthood (mid-life). We observed that monorden significantly improved animals' maximum velocity in mid-life compared with controls ([Figure 4](#fig4){ref-type="fig"}C; [Table S4](#mmc5){ref-type="supplementary-material"}).

Taken together, these findings show that monorden improves the healthspan in addition to conferring lifespan-extending effects, a phenotype extremely desirable when a geroprotective drug should be applied to humans for the benefit of healthy aging.

Hsp90 Inhibitors Represent a Potential Pharmacological Class of Geroprotective Compounds that Act through the Heat Shock Transcription Factor HSF-1 {#sec2.6}
---------------------------------------------------------------------------------------------------------------------------------------------------

To better understand how Hsp90 inhibition leads to these improvements in lifespan and healthspan, we investigated the transcriptional responses to monorden treatment, comparing them with those of the established geroprotectors rapamycin and LY-294002. From the original CMap transcriptomes, we chose three datasets generated from the same cell line (MCF7) as representative examples. Clustering analysis revealed that the effects of rapamycin and LY-294002 are much more similar to each other than they are to the effects of monorden ([Figure 5](#fig5){ref-type="fig"}A; [Table S6](#mmc7){ref-type="supplementary-material"}). This may be expected because rapamycin and LY-294002 each target a single kinase in a nutrient-sensing pathway ([@bib74]), whereas the effects of Hsp90 inhibitors should be much broader. In the same analysis, several transcript clusters emerged, defining the differences between the three treatments. One of these clusters stood out as being strongly upregulated upon monorden treatment but not upon treatment with rapamycin or LY-294002 ([Figure 5](#fig5){ref-type="fig"}A, yellow). Using Gene Ontology (GO) term enrichment analysis, we identified this cluster to be dominated by the unfolded protein response; i.e., an upregulation of heat shock proteins (HSPs) ([Figure 5](#fig5){ref-type="fig"}B; [Table S6](#mmc7){ref-type="supplementary-material"}).Figure 5Hsp90 Inhibitors and the Transcriptional Landscape of Geroprotective Drugs(A) Heatmap clustering analysis of monorden-, LY-294002-, and rapamycin-induced transcriptomic changes (CMap data). Lines represent transcripts. Only those changing at least 1.5-fold are shown. Five main transcript clusters emerge, indicated in different colors: blue, purple, light green, dark green, and yellow. See [Table S6](#mmc7){ref-type="supplementary-material"} for the genes present in the transcript clusters.(B) The ten most enriched GO terms within the five clusters from (A). See [Table S6](#mmc7){ref-type="supplementary-material"} for all enrichments.(C) Heatmap clustering analysis of the transcriptomic changes induced by all CMap compounds that are listed as lifespan-extending in the DrugAge database, including previously undocumented compounds discovered by our study (monorden, tanespimycin, and felbinac). The bottom two rows indicate candidate compounds described in this study (black tiles) and any known Hsp90 inhibitors (green tiles). Lines represent transcripts; only transcripts changing at least 2-fold in any given drug were used for clustering and are shown. See [Table S6](#mmc7){ref-type="supplementary-material"} for all the transcripts used in the clustering analysis. The yellow box indicates a cluster of HSPs upregulated by monorden, tanespimycin, geldanamycin, and celastrol, all of which are known Hsp90 inhibitors. See [Table S6](#mmc7){ref-type="supplementary-material"} for the transcripts comprising and the GO term enrichments within the yellow cluster.(D) Heat shock survival assay performed at 35°C. See [Table S4](#mmc5){ref-type="supplementary-material"} for worm numbers and statistics.(E) Lifespan analysis for solvent control- and monorden-treated N2 and *hsf-1(sy441)* animals. See [Table S4](#mmc5){ref-type="supplementary-material"} for worm numbers and statistics.(F) Model of how Hsp90 inhibitors such as monorden and tanespimycin may confer their geroprotective effects. Hsp90 inhibitors lead to release of the transcription factor HSF1 from sequestration by Hsp90 proteins, allowing HSF1 to trimerize and activate transcription of its target genes in the nucleus, most importantly HSPs/chaperones. These HSPs/chaperones help to ensure the correct folding of proteins and prevent their aggregation with age, promoting protein homeostasis and cytoprotection, which lead to improved health and longevity.

Having established the distinguishing ability of monorden to induce the unfolded protein response compared with rapamycin and LY-294002, we then asked how unique this ability really is, also in the broader landscape of all known geroprotectors. We thus extended our transcriptomic evaluation to all drugs that are described in DrugAge to extend lifespan and that are present in CMap. We generated transcriptomes representative of a drug response by averaging multiple instances of the same drug in CMap, and then we clustered these transcriptional profiles into a large heatmap, also including the geroprotective candidate compounds identified by our study ([Figure 5](#fig5){ref-type="fig"}C; [Table S6](#mmc7){ref-type="supplementary-material"}). To see how the unfolded protein response was modulated in this transcriptional landscape and to determine whether this was a unique ability of monorden or Hsp90 inhibitors, we looked for transcript clusters particularly enriched for genes related to the unfolded protein response, and in particular the upregulation of HSPs and chaperones. One cluster in particular caught our attention ([Figure 5](#fig5){ref-type="fig"}C, highlighted in yellow; see [Table S6](#mmc7){ref-type="supplementary-material"} for GO enrichments in this cluster). This cluster is highly enriched for genes of the unfolded protein response, including HSPs from the HSP70 class (HSPA4L, HSPA6, and ASPA7), the HSP40 class (DNAJA1, DNAJC3, and DNAJB6), larger (HSPH1), and small (HSPB1) HSPs, among others ([Table S6](#mmc7){ref-type="supplementary-material"}). [Figure 5](#fig5){ref-type="fig"}C shows that only four compounds are clear activators of this transcript cluster. Strikingly, all of these are known Hsp90 inhibitors: monorden, tanespimycin, celastrol, and geldenamycin. Celastrol is a pentacyclic triterpenoid ([@bib41]) described to induce heat shock response ([@bib102], [@bib108]) and has been shown previously to increase the lifespan of *C. elegans* by 17% ([@bib45]). Geldanamycin is a 1,4-benzoquinone ansamycin antibiotic. In *C. elegans*, a prior study failed to observe robust lifespan and healthspan benefits from this drug ([@bib11]). However, it has been argued that geldanamycin actually fails to bind *C. elegans* Hsp90 because of it harboring minor structural differences from the human protein ([@bib19]). In light of the mostly side-effect-free lifespan benefits of the other three Hsp90 inhibitors, we therefore suggest that geldanamycin might indeed not function as an Hsp90 inhibitor in *C. elegans* and, instead, cause off-target effects. Taken together, the above observations show that Hsp90 inhibitors generally lead to an upregulation of HSPs/chaperones, a feature that is unique and defines them as a potential pharmacological class among geroprotectors.

It is well established that increased stress resistance can slow down the aging process and thereby improve organismal health and longevity. HSP upregulation confers such stress resistance by improving the organism's protein homeostasis. Thus, we hypothesized that HSP upregulation comprises the mechanism by which Hsp90 inhibitors confer their beneficial effects on health and lifespan. To confirm this, we first tested whether a process that is particularly dependent on HSPs---namely, resistance to heat-induced unfolded protein stress---can be improved by monorden. Thus, we grew *C. elegans* at 20°C, exposed them to monorden from the L4 stage onward, and, on day 1 of adulthood, shifted them to 35°C. In line with our hypothesis, we found that monorden-treated animals survived significantly longer under these conditions ([Figure 5](#fig5){ref-type="fig"}D; [Table S4](#mmc5){ref-type="supplementary-material"}). This observation shows that monorden not only extends the lifespan but also improves resistance to heat stress, an ability that is well known to depend on HSP induction ([@bib110]). Further, it illustrates that upregulation of HSPs by monorden is functionally relevant and may well be the key mechanism of its geroprotective effects. To further support this notion, we turned to evaluation of the conserved transcription factor HSF-1. HSF-1 is a master regulator of the cytosolic unfolded protein response in eukaryotes, required for the upregulation of HSPs upon unfolded protein stress. HSF-1 protein abundance increases upon heat shock, and artificial overexpression of HSF-1 and the resulting HSP induction have been found to be sufficient to increase lifespan in worms ([@bib43]). In accordance with this, we observed a significant increase in HSF-1 protein levels upon monorden treatment ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Furthermore, we tested whether a hypomorphic allele of the *hsf-1* gene, *hsf-1(sy441)*, would be able to suppress the lifespan extension phenotype caused by monorden. Indeed, we found this to be the case ([Figure 5](#fig5){ref-type="fig"}E; [Table S4](#mmc5){ref-type="supplementary-material"}).

Because HSF-1 is a transcription factor and its loss suppresses the lifespan benefits of monorden treatment, one would assume that monorden confers its benefits by HSF-1-induced transcriptional changes. To test this, we conducted gene expression analyses by mRNA sequencing (mRNA-seq). First, we treated wild-type *C. elegans* from the L4 stage onward with monorden or a solvent control and determined their transcriptomes on day 3 of adulthood to define the genes whose expression changes upon monorden treatment. This identified 825 transcripts that were induced and 993 transcripts that were repressed by monorden treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Then we conducted the same comparison in *hsf-1(sy441)* mutant animals. Consistent with HSF-1 conferring much of the transcriptional changes induced by monorden treatment, most of the monorden-induced gene expression changes were lost in *hsf-1(sy441)* animals ([Figure S6](#mmc1){ref-type="supplementary-material"}C). To further support the notion that monorden confers its effects through HSF-1, we determined the genes activated by HSF-1 upon heat shock and compared them with the genes activated by monorden in wild-type animals. Here we found a significant overlap between both gene sets ([Figure S6](#mmc1){ref-type="supplementary-material"}D), showing that many of the genes HSF-1 activates under proteotoxic stress also become activated by monorden treatment.

In light of all these data, and because it has also been well established that Hsp90 functions as an inhibitor of HSF-1 ([@bib115]), we eventually propose the following mechanistic cascade to cause prolonged lifespan and health in *C. elegans*: compounds like monorden and tanespimycin cause inhibition of Hsp90, which, in turn, causes activation of HSF-1. HSF-1, as a transcription factor, then upregulates the expression of heat stress response proteins, leading to improved protein homeostasis throughout age and, thereby, the compounds' geroprotective effects ([Figure 5](#fig5){ref-type="fig"}F).

Hsp90 Inhibition Shows Good Utility as a Combinatorial Treatment with Other Geroprotectors {#sec2.7}
------------------------------------------------------------------------------------------

By now we had established that Hsp90 inhibitors lead to rather distinct transcriptional responses, including a unique ability to upregulate HSPs, compared with other geroprotectors in our transcriptome clustering analysis ([Figure 5](#fig5){ref-type="fig"}C). Thus, we hypothesized that Hsp90 inhibitors may provide excellent complementing capabilities when used in combinatorial treatments with other geroprotectors, resulting in additive beneficial effects on lifespan. To test this, we treated worms with 50 μM of monorden, rapamycin, or LY-294002 as well as combinations of 50 μM rapamycin and 50 μM Monorden or 50 μM LY-294002 and 50 μM monorden ([Figure 6](#fig6){ref-type="fig"}; [Table S4](#mmc5){ref-type="supplementary-material"}). Indeed, monorden treatment was able to significantly extend the lifespan of either rapamycin-treated (p \< 0.01) or LY-294002-treated (p \< 0.01) animals by an additional ∼20%. In contrast, increasing the dose of monorden alone did not lead to additional lifespan extension ([Figure S3](#mmc1){ref-type="supplementary-material"}E; [Table S4](#mmc5){ref-type="supplementary-material"}). This latter finding is also consistent with monorden concentrations beyond 50 μM failing to further increase the monorden-driven induction of HSF-1 protein levels ([Figure S6](#mmc1){ref-type="supplementary-material"}A).Figure 6Additive Effects of Monorden Treatment with Other Geroprotective Compounds(A) Lifespan assay of worms treated with either a solvent control, monorden alone, rapamycin alone, or the combination of monorden and rapamycin. The latter combinatorial treatment shows an increased lifespan benefit (p \< 0.01, log rank test).(B) Lifespan assay of worms treated with a solvent control, monorden alone, LY-294002 alone, or the combination of monorden and LY-294002; likewise, this shows additive benefits of the compounds (p \< 0.01, log rank test).See [Table S4](#mmc5){ref-type="supplementary-material"} for worm numbers and statistics.

In summary, monorden appears to target geroprotective pathways that are at least in part distinct from those targeted by rapamycin and LY-294002. This highlights Hsp90 inhibitors not only as good geroprotectors when used by themselves but also as compounds that may further enhance the benefits of other geroprotectors by targeting distinct but complementing pathways.

Discussion {#sec3}
==========

Here we established a powerful strategy for the discovery of geroprotective compounds using age classifiers derived from age-stratified human tissue transcriptomes and applying them to a database of drug-induced transcriptomic changes in human cell cultures. We reasoned that our strategy would be able to identify drugs that produce a "youthful" transcriptional signature and reveal candidate geroprotective compounds. Indeed, when applying this strategy to datasets from the GTEx consortium and CMap, we obtained geroprotector candidates, many of which we could validate as being lifespan-extending in *C. elegans*. This led to confirmation of the lifespan-extending abilities of known geroprotectors like tyrphostin AG-1478, LY-294002, and rapamycin. But more importantly, we identified geroprotectors that never before had been described to prevent aging or extend the lifespan in any organism; namely, felbinac, monorden, and tanespimycin. By eventually focusing on monorden and tanespimycin, we implied the existence of a very potent class of geroprotectors that act via Hsp90 inhibition and concomitant induction of stress response gene expression, in particular of the cytosolic unfolded protein response.

Hsp90 is a chaperone protein that accounts for about 1%--2% of all proteins in the cell ([@bib75], [@bib106], [@bib107]) and that, together with co-chaperones and Hsp70, forms a sophisticated chaperone machinery ([@bib76]). Specifically, Hsp90 mostly serves to fold but sometimes also to regulate or even aid with the degradation of over 200 so-called "client proteins" that are enriched for both protein kinases and transcription factors ([@bib76], [@bib101]). Several of the clients it helps to fold are growth-promoting or even oncogenic, including protein kinase B (AKT), mechanistic target of rapamycin (mTOR), ERBB2, BCR-ABL, C-RAF, CDK4, various steroid hormone receptors, and telomerase ([@bib9], [@bib22], [@bib75]). Consistent with this growth-promoting role, substantial depletion of Hsp90 can lead to growth arrest during *C. elegans* development or tends to shorten the animals' lifespan ([@bib86]; [Figure S4](#mmc1){ref-type="supplementary-material"}A). Nevertheless, our work suggests that mild impairment of Hsp90 combined with the appropriate timing is actually beneficial, improving the organism's healthspan and lifespan.

Because of its role in folding of growth-promoting kinases, Hsp90 has been widely acknowledged as a therapeutic target to fight cancer in humans ([@bib10], [@bib75], [@bib109]). By now, pharma companies have filed over 30 patents for compounds that target Hsp90 ([@bib83]). Pharmacological impairment of Hsp90 can occur in a variety of ways. Most Hsp90 inhibitors block the ATP binding site of Hsp90 (e.g., monorden, tanespimycin, and geldanamycin; [@bib77], [@bib81], [@bib93]), but others can also disrupt co-chaperone or client interactions (e.g., celastrol; [@bib13]) or interfere with post-translational modifications of Hsp90 ([@bib54]). The first described inhibitors of Hsp90 were naturally occurring compounds, including geldanamycin and monorden. Clinical exploration of geldanamycin was halted, however, because of toxic side effects. Eventually, structural analogs of geldanamycin with lower toxicity were developed ([@bib9], [@bib92]). Tanespimycin is such an analog and has already led to more promising results in clinical trials ([@bib3], [@bib70], [@bib82]). Structural variants of monorden that improve its potency and stability have also been developed with promising results ([@bib85]), and our work prompts their consideration as geroprotectors in the future.

Besides disrupting growth-promoting and oncogenic pathways, Hsp90 inhibitors also have a well-documented ability to induce the cytosolic unfolded protein response ([@bib14], [@bib61]). This induction is thought to occur through the heat shock transcription factor HSF1, a client protein of Hsp90 ([@bib101]). Upon Hsp90 inhibition, HSF1 becomes activated by dissociating from Hsp90 and undergoing trimerization as well as nuclear translocation. When in the nucleus, HSF1 promotes the expression of heat shock response genes, including HSPs/chaperones ([@bib115]). In the context of cancer therapy, this is an undesirable side effect of Hsp90 inhibitors because HSPs may serve to protect cancerous cells. To avoid these consequences, HSF1 repressors have been developed for combinatorial use with Hsp90 inhibitors ([@bib101]). In the context of aging, however, this activation of HSF1 should be beneficial. Consistently, overexpression of HSF1 has been shown to increase the lifespan in *C. elegans* ([@bib2], [@bib43]), and we show in [Figure 5](#fig5){ref-type="fig"}E that the lifespan-extending benefits of Hsp90 inhibition are abrogated by removal of HSF1 function. Taken together, we have identified Hsp90 inhibition as a potent strategy to improve healthspan and lifespan through the transcription factor HSF1 and, presumably, its ability to induce stress response genes; i.e., HSPs.

Interestingly, although Hsp90 inhibition leads, via this mechanism, to remarkable geroprotection in *C. elegans*, the geroprotective benefits in humans may even be greater. Previous work has shown that there are two hallmarks of human aging that do not exist in *C. elegans* and that additionally can be targeted by Hsp90 inhibition: (1) chronic inflammation and (2) the presence of senescent cells. Hsp90 inhibitors are able to suppress inflammation by blocking immune cell activation ([@bib103]), and a recent screen identified Hsp90 inhibitors to be senolytic agents ([@bib26]). Thus, Hsp90 inhibition might confer geroprotection through multiple mechanisms in humans, involving improved protein homeostasis ([@bib16], [@bib28], [@bib87]), as described in our study, but likely also through decreased inflammation ([@bib114]) and removal of senescent cells ([@bib26]).

The findings of [@bib26] are of particular note because they observed that the Hsp90 inhibitor 17-DMAG could improve the healthspan in a progeroid mouse model, establishing Hsp90 inhibitors' healthspan benefits in a mammalian context. In their study, Hsp90 inhibitor treatment correlated with an improved healthspan, which further correlated with a reduction in p16INK4a expression, a marker of senescent cells. Notably though, a causal link between clearance of senescent cells and the improved healthspan in these mice has yet to be shown, raising the possibility that the healthspan benefits observed in this study occurred independently of changes in senescent cells or may, at least in part, have been due to the mechanisms we propose in our work; namely, through HSF1 activation and improved protein homeostasis. Likewise, the authors demonstrated improvement of healthspan by Hsp90 inhibition in a progeroid model, but an improvement of healthspan and lifespan in a wild-type context still remains to be tested. Our work argues that both healthspan and lifespan will be improved in a wild-type animal context, too. In any case, the exciting fact that Hsp90 inhibitors influence multiple hallmarks of aging and the questions of how this occurs and whether these effects may synergize to improve health and lifespan in humans warrant further analysis.

Finally, we evaluated the utility of Hsp90 inhibitors for combinatorial treatments because they confer distinct and complementary gene expression changes compared with other known geroprotective drugs. Indeed, we could show *in vivo* in *C. elegans* that Hsp90 inhibition yields additive lifespan benefits when combined with mTOR or PI3K inhibitors. Thus, future studies of Hsp90 inhibitors as geroprotectors in humans should consider their combinatorial use, too.

Taken together, our study provides an innovative state-of-the-art approach to discover geroprotective compounds and highlights Hsp90 inhibition as a potential therapeutic approach to defer aging and age-related complications. Several well-developed Hsp90 inhibitors are already available that could be repurposed for such use and future work in humans will have to determine their full potential.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-HSF1Thermo FisherCat\#PA3-017; RRID:[AB_325968](nif-antibody:AB_325968){#interref0105}Mouse monoclonal anti-ActinMilliporeCat\#MAB1501; RRID:[AB_2223041](nif-antibody:AB_2223041){#interref0110}**Bacterial and Virus Strains***Escherichia coli* OP50-1Caenorhabditis Genetics Center (CGC)Cat\# OP50-1; RRID:WB-STRAIN:OP50-1*Escherichia coli* HT115, containing plasmid L4440[@bib47]N/A*Escherichia coli* HT115, containing hsp90 RNAi plasmid \#1[@bib79]N/A*Escherichia coli* HT115, containing hsp90 RNAi plasmid \#2[@bib65]N/A**Chemicals, Peptides, and Recombinant Proteins**Dimethyl sulphoxideSigma AldrichCat\#D2650Valproic acidSigma AldrichCat\#S0930000Trichostatin ASigma AldrichCat\#T8552TanespimycinSigma AldrichCat\#A8476FulvestrantSigma AldrichCat\#I4409LY-294002Sigma AldrichCat\#L9908EstradiolSigma AldrichCat\#E8875RapamycinSigma AldrichCat\#37094HaloperidolSigma AldrichCat\#H1512ProchlorperazineSigma AldrichCat\#P9178GenisteinSigma AldrichCat\#G6649TrifluoperazineSigma AldrichCat\#T8516SantoninSigma AldrichCat\#Y0001052TretinoinSigma AldrichCat\#R2625MonordenSigma AldrichCat\#R2146WortmanninSigma AldrichCat\#W16281,5-isoquinolinediolSigma AldrichCat\#I138DexverapamilSigma AldrichCat\#V4629FisetinSigma AldrichCat\#F4043LuteolinSigma AldrichCat\#L9283CantharidinSigma AldrichCat\#C7632DL-PPMPSigma AldrichCat\#P4194Tyrphostin AG-1478Sigma AldrichCat\#T4182ApigeninSigma AldrichCat\#A3145AdiphenineSigma AldrichCat\#A3649IsoflupredoneSigma AldrichCat\#1348907FelbinacSigma AldrichCat\#Y0000731Prestwick-983Sigma AldrichCat\#D7571NU-1025Sigma AldrichCat\#N72875186223ChemBridgeCat\#5186223**Critical Commercial Assays**Direct-zol RNA MiniPrep kitZymo ResearchCat\#R2052TruSeq RNA SamplePrep V2 kitIlluminaCat\#RS-122-2001/2**Deposited Data**mRNA-seq data (deposited at the SRA (NCBI))This studyPRJNA523315**Experimental Models: Organisms/Strains***C. elegans* N2 (wild type)CGCCat\# N2\_(ancestral); RRID:WB-STRAIN:N2\_(ancestral)*C. elegans eri-1(mg366)*CGCCat\# GR1373; RRID:WB-STRAIN:GR1373*C. elegans hsf-1(sy441)*CGCCat\# PS3551; RRID:WB-STRAIN:PS3551**Software and Algorithms**OASIS 2[@bib36]<https://sbi.postech.ac.kr/oasis2/>ImageJImageJ<https://imagej.net/Welcome>GeroprotectorPredictorThis study<http://riedellab.org/downloads/GeroprotectorPredictor.7z>GraphPad Prism 7.05GraphPad<https://www.graphpad.com/>ExcelMicrosoft<https://products.office.com/en-us/?rtc=1>RR Project<https://www.r-project.org/>TopHat 2[@bib99]<https://ccb.jhu.edu/software/tophat/index.shtml>Cuffdiff 2[@bib100]<http://cole-trapnell-lab.github.io/cufflinks/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Christian G. Riedel (<christian.riedel@ki.se>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

*Caenorhabditis elegans* were maintained on NGM plates ([@bib89]) and fed with *Escherichia coli* OP50-1 unless stated otherwise. *C. elegans* strains used in this study were N2 (wild-type), GR1373 (*eri-1(mg366)*) ([@bib48]), and PS3551 (*hsf-1(sy441)*) ([@bib34]), also listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. All experiments were conducted using hermaphrodites. Animals were synchronized by bleaching and exposed to drugs or RNAi bacteria at different developmental or adult stages, which are indicated in the results, figure legends, or later sections.

Method Details {#sec4.4}
--------------

### Pre-processing of the GTEx data {#sec4.4.1}

The publicly available Version 6 of the GTEx Transcriptome datasets (accessed April 2016, dbGaP Accession phs000424.v6.p1) and annotation files (subject and sample attributes) were downloaded from the GTEx portal (<https://gtexportal.org/home/datasets>). Transcriptome data was loaded using the 'read.gct' function in the 'CePa' package (Centrality-based pathway enrichment) ([@bib31]) into R. Data was preprocessed as previously described ([@bib30], [@bib63], [@bib95]): Data was normalized to 1 million reads, low abundant transcripts were removed by selecting RPKMs whose values were less than 0.1 in at least 80% of samples. A pseudocount of 1 was added and data was log2-transformed. Transcriptomes were filtered to contain only those with an RNA integrity score (RIN) greater or equal to 6 (the SMRIN column of the annotation file) and for those that were deemed usable by the GTEx consortium (the SMAFRZE column of the annotation file). For data processing, GTEx files were parsed into sub files by tissue. In summary this resulted in a dataset of 8555 transcriptomes covering 19343 transcripts in 51 tissues. These sub files were divided further by gender and decade-sized age bins.

### Processing of the GTEx data for age-related comparisons {#sec4.4.2}

Genders were treated separately, and all tissues were systematically processed in the same way. Tissues were individually loaded and parsed into age bins. 'Old' was considered to be the age bin of 60-69 (the age bin of 70-79 was omitted due to low sample numbers), and 'young' was considered to be any of the age bins of 20-29, 30-39, 40-49, or 50-59, which then would be compared to the old age-bin in a binary fashion. Young age groups were compared to the old, only when both groups contained at least 10 transcriptomes each. Next, the following steps were performed for the binary comparisons: Transcriptomes were reduced to only contain transcripts in common between the GTEx and CMap datasets (10,890 transcripts). Transcriptomes were further filtered to remove low abundant transcripts (the 10% least abundant). To aid the model building, a feature reduction step was undertaken by keeping only those transcripts which showed differential expression between the young and old age bin (p \< 0.01). This was achieved by the 'rowttests' function in the R package 'genefilter' ([@bib27]). Any cell line-based data in GTEx was omitted from our study.

### Random Forest model generation and selection {#sec4.4.3}

For each binary comparison of 'old' transcriptomes to any given 'young' transcriptomes prepared above, data was reduced to have equal numbers of samples in each age group. Data was split into 70% used for model generation and 30% reserved for model validation, utilizing the 'createDataPartition' function in the R package 'caret' ([@bib50]). The 70% data partition was centered and scaled using the 'preProcess' function of the same R package. Next, the R package 'Random Forest' ([@bib55]) was implemented using the 'train' function again in the 'caret' package and was used to train models, using repeated cross validation (10-fold), using the default setting of 500 trees per forest, and using a standardized grid that varied the number of variables randomly selected per data split (varying .mtry in the tunegrid parameter). Models were automatically tuned, selecting the parameters with the best performing receiver-operating characteristic (ROC). Final models were tested on the remaining 30% data split for accuracy. 182 models were generated in this way. Performance of the models on the testing dataset was assessed using the 'performance' function in the R package 'ROCR' ([@bib84]). Final models were evaluated based on the ROC, the sensitivity, and the specificity achieved during model training, and the ROC and accuracy determined during model testing. Only those passing cutoff criteria above 0.75 in all these domains were retained. This resulted in 24 final models, our age-classifiers, able to distinguish young transcriptomes from those in the old age group of 60-69 years. Fourteen models derived from male tissues, from the adrenal gland (age 40-49), the coronary artery (age 40-49), mammary breast tissue (age 40-49), the transverse colon (age 40-49), the gastresophageal junction of the esophagus (age 40-49), the pancreas (age 40-49 and also 30-39), the aorta artery (30-39), the esophagus muscularis (age 30-39), suprapubic skin, not sun exposed (age 30-39 and also 20-29), the thyroid (age 30-39), and the prostate (age 20-29). Ten models derived from female tissues, from the adrenal gland (age 50-59, and also 40-49), the coronary artery (age 50-59, and also 40-49), the liver (age 50-59), the pituitary (age 50-59), the vagina (age 50-59, and also 40-49), the gastresophageal junction of the esophagus (age 40-49), and the heart's atrial appendage (age 40-49).

### Connectivity Map data preparation {#sec4.4.4}

Information on the Connectivity Map (CMap) instances (drug perturbation IDs and descriptions) was accessed through the R package 'ConnectivityMap' ([@bib71]). A corresponding matrix of 'amplitudes' (a measure of the extent of differential expression of a given probe set) was obtained by download from the Broad Institute's FTP server (<ftp://ftp.broadinstitute.org/distribution/cmap>). The CMap amplitude matrix was converted to a fold change (log2) matrix using the conversion equation provided at <https://www.broadinstitute.org/cmap/help_topics_frames.jsp>. In order to later apply the CMap fold change data to the GTEx dataset, we converted the affymetrix probe IDs used in CMap to Ensemble gene IDs (used in GTEx) through the R package 'biomaRt' ([@bib20], [@bib21]). For each GTEx gene entry, the corresponding probe fold change entries from CMap were collapsed to one value (if needed) in a conservative fashion by taking the median entry. Of the 19434 transcript entries in GTEx, we found 10869 to have corresponding CMap entries. Finally, the data was converted to linear scale, which resulted in a CMap dataset of fold changes that could be applied to transcriptomes from the GTEx dataset.

### Generating 'drug-induced' transcriptomes for age classification {#sec4.4.5}

For each specific model, derived from a gender, tissue, and binary age group comparison within the GTEx dataset, the transcriptome of a corresponding 'prototypical' age was generated, representing an average transcriptome between the compared old and young datasets. This was done by first determining the median transcriptional profile in the young and old datasets separately and subsequently averaging the two. This resulted in 24 prototypical transcriptomes, one for each model, which we termed 'middle age'. The processed CMap fold changes were then applied to each of these middle-aged transcriptomes, generating datasets that we term 'drug-induced' transcriptomes, which are specific for each model. These transcriptomes are then ready to be used for age classification.

### Application of age classifiers to 'drug-induced' transcriptomes and the eventual ranking of geroprotectors {#sec4.4.6}

"Drug-induced" transcriptomes were classified by their respective models, returning probability scores of being 'young'. This resulted in 6100 CMap perturbation transcriptomes receiving a classification from each of the 24 models. For each drug present in replicate or various conditions in CMap, only a single score was used per model, namely the score from the most geroprotective prediction. This resulted in each drug being assessed for its geroprotective potential 24 times (once for each model), regardless of the number of replicates or conditions in CMap. To compare between models, these predictions were normalized to a maximal value of 0.5 and subsequently centered around 0, resulting in what we refer to as a 'geroprotective index'. Finally, each drug was given a geroprotective ranked score, by seeing how many of the 24 predictions placed the drug above the mean absolute deviation of the consolidated distribution of all geroprotective index scores ([Figure 2](#fig2){ref-type="fig"}C), and a p value was generated using the hypergeometric function with a Benjamini correction.

### DrugAge {#sec4.4.7}

The DrugAge database ([@bib5]) was accessed in May 2017, and was filtered to include all drugs that significantly increase lifespan.

### Gene ID conversion {#sec4.4.8}

Where needed and unless otherwise specified, we used the BIOMART website (<http://www.ensembl.org//useast.ensembl.org/biomart?redirectsrc=//www.ensembl.org%2Fbiomart>) with the Human gene dataset (GRCh38.p10), to convert between Ensemble Stable Gene IDs and other gene names.

### GO term enrichments {#sec4.4.9}

Gene functional enrichments were determined by using the DAVID Bioinformatics Resources (version 6.8) ([@bib44]). Corresponding background gene lists were used for each enrichment analysis (see [Table S6](#mmc7){ref-type="supplementary-material"}). Annotation clusters determined by DAVID (groupings of related genes based on the agreement of sharing similar annotation terms) having an enrichment score of \> 1 were selected for consideration. A representative naming for the enrichment was selected after evaluation of the annotation cluster's GO terms.

### Data Visualizations {#sec4.4.10}

Data was visualized using R ([@bib78]) with color schemes selected from there or the RColorBrewer package ([@bib67]).

### RNAi by feeding {#sec4.4.11}

*C. elegans* were grown on the *E. coli* strain HT115 without plasmid until the required stage, then washed in M9 buffer containing antibiotics (Tetracyclin, Carbenicillin, and Streptomycin) to remove these bacteria, and finally transferred to HT115 containing dsRNA-expressing plasmids targeting *daf-21*. These *daf-21* RNAi bacteria were obtained from published sources: Clone 1 ([@bib79]); clone 2 ([@bib65]). HT115 containing empty plasmid L4440 ([@bib47]) was used as a negative control.

### Compounds {#sec4.4.12}

The following compounds were purchased from Sigma Aldrich: Dimethyl sulphoxide (DMSO, ref. D2650), Valproic acid (ref. S0930000), Trichostatin A (ref. T8552), Tanespimycin (ref. A8476), Fulvestrant (ref. I4409), LY-294002 (ref. L9908), Estradiol (ref. E8875), Rapamycin (ref. 37094), Haloperidol (ref. H1512), Prochlorperazine (ref. P9178), Genistein (ref.G6649), Trifluoperazine (ref. T8516), Santonin (ref. Y0001052), Tretinoin (ref. R2625), Monorden (ref. R2146), Wortmannin (ref. W1628), 1,5-isoquinolinediol (ref. I138), Dexverapamil (ref. V4629), Fisetin (ref. F4043), Luteolin (ref. L9283), Cantharidin (ref. C7632), DL-PPMP (ref. P4194), Tyrphostin AG-1478 (ref. T4182), Apigenin (ref. A3145), Adiphenine (ref. A3649), Isoflupredone (ref. 1348907), Felbinac (ref. Y0000731), Prestwick-983 (ref. D7571), NU-1025 (ref. N7287). The compound '5186223' was purchased from ChemBridge. Compounds were dissolved in water, ethanol, or DMSO, in concentrations as specified ([Table S4](#mmc5){ref-type="supplementary-material"}). For all compounds dissolved in DMSO, DMSO concentration in drug and control plates was kept at 0.33% (v/v), as recommended by several studies ([@bib11], [@bib112]). Ethanol concentrations were likewise kept at 0.33% (v/v). Two compounds, Fulvestrant and 5186223 required higher final DMSO concentrations (0.66% (v/v)) due to solubility issues.

### Preparation of drugged NGM plates {#sec4.4.13}

NGM plates for lifespan and healthspan assays were identical to the maintenance plates mentioned above, with two exceptions: 1) Ampicillin (100 μg/ml) was added to the plates, and 2) the plates were seeded with dead instead of live OP50-1 bacteria, to avoid secondary effects from bacterial drug metabolism. The bacteria were killed by heat. Finally, drugs or solvent controls were added to the plates, and the plates then incubated over night at room temperature, before the worms were added.

### Lifespan assays {#sec4.4.14}

*C. elegans* were grown in a synchronized way and divided among at least 4 plates (3 cm) per condition, with approximately 30 worms per plate. At the L4 stage, plates were treated with 0.1 g/ml 5-Fluoro-2′-deoxyuridine (FUDR) to prevent progeny production ([@bib35]). The animals' survival was recorded and analyzed by a fully automated 'lifespan machine', as previously described ([@bib90]). To ensure high quality results, lifespan curves were assessed, only if they were derived from at least 50 tracked worms. Data assessment was conducted using the 'Survival' package in R ([@bib97]) with Kaplan-Meier estimated survival curves compared to each other using the log-rank test. For the lifespan experiments shown in [Figures 3](#fig3){ref-type="fig"}E, 3G, and [S4](#mmc1){ref-type="supplementary-material"}A, identical procedures were followed, except that survival of animals was examined manually every 2-3 days as previously described ([@bib35]), and the data was assessed by OASIS2 ([@bib36]).

### Heat-stress assay {#sec4.4.15}

Synchronized N2 animals were grown and transferred to drugged or solvent control NGM plates as described for lifespan assays. At day 1 of adulthood, animals were shifted to 35°C, and their survival was recorded and analyzed by the 'lifespan machine' as previously described ([@bib90]).

### Healthspan analysis: Population activity assay {#sec4.4.16}

To derive 'activity curves' of worm populations as a healthspan measure from our 'lifespan machine' data, we utilized the 'animal_position.csv' output file that contains positions of 'worm objects' detected by the software. These are objects that the software presumes to be worms. We reconstructed the image space by creating a binary matrix corresponding to 'non-worm' (0) and 'worm' (1) positions, as indicated by the file, and as plotted in [Figure S5](#mmc1){ref-type="supplementary-material"}A. Converting this binary image matrix to a linear vector allowed for Pearson's correlations between time points to be calculated. We compared in this way every time point (n) with the one occurring directly subsequent to it (n+1) (see [Figure S5](#mmc1){ref-type="supplementary-material"}A for illustration), generating a time-based correlation of worm positions ([Figure S5](#mmc1){ref-type="supplementary-material"}B). A higher correlation between two adjacent time points was interpreted as less movement of the worms, indicative of lower 'health' of the population. Data from time points beyond the death of the worm population were omitted, to avoid artifacts. Combining these correlations from independent NGM plates, generated a large representative plot of time-based correlations, reflecting the worm population's activity in time on the plates ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Fitting these correlations with a linear smoothing spline, using the preinstalled smooth.spline function in R, produced a curve that could be interpreted as movement of worms on the plates at the population level ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We subsequently made simple assumptions to plot this as a more familiar 'curve' for visual comparison between drug treatments and controls. Namely, 1) we mirrored and normalized the correlations, scaling them from 1 ('most active') to 0 ('least active'), where we assumed that the highest correlation was the 'least active' time point and the lowest correlation was the 'most active' time point. 2) We assumed that the 'most active' time point represented the population optimum, and set all previous values to this. Further, we assumed that the 'least active' time point represented the end of movement on the plate, and set all subsequent time points to that value. Performing this for drug treatment and control conditions, allowed to assess a compound's influence on the activity of a worm population as a measure of the population's healthspan ([Figure 4](#fig4){ref-type="fig"}A).

### Healthspan analysis: Maximum velocity assay {#sec4.4.17}

Individual worms' maximum velocity was measured as previously described ([@bib33]). In brief, synchronized N2 animals were grown and transferred to drugged or solvent control NGM plates, as was done for lifespan assays. On day 1 and day 4 of adulthood, individual worms were transferred to individual NGM plates without bacteria. The worms' movement was video-recorded immediately for 30 s (10 frames per second), and the velocity profile was analyzed using the ImageJ plugin 'wrMTrck' ([@bib69]) and Microsoft Excel. Population distributions were assessed using the Wilcoxon-Mann-Whitney test from the preinstalled 'wilcox.test' function in R.

### Healthspan analysis: Thrashing assay {#sec4.4.18}

Synchronized N2 animals were grown and transferred to drugged or solvent control NGM plates, as was done for lifespan assays. As the only difference, here 24-well plates were used. On day 1 and day 13 of adulthood, worms were measured for body bend movement in liquid. In brief, M9 was added to individual plate wells and videos were immediately recorded for a duration of 2 minutes (at 20 frames per second). Body bends were measured using the ImageJ plugin 'wrMTrck' ([@bib69]). Population distributions were assessed using the Wilcoxon-Mann-Whitney test from the preinstalled 'wilcox.test' function in R.

### Dauer assays {#sec4.4.19}

Wild-type *C. elegans* were synchronized by bleaching, the resulting eggs immediately dropped onto plates, and then grown for 52 hours at 27°C on life OP50-1 bacteria. Dauer formation was determined by scoring the animals' survival after 30 min in 1% (w/v) SDS. Results were derived from four biological replicate experiments with \> 100 worms per condition.

### Whole worm lysis and western blotting {#sec4.4.20}

Around 200 animals were harvested, washed three times with cold M9 buffer, and then resuspended in cold M9 supplemented with Complete (Roche), 1 mM sodium orthovanadate, 25 mM sodium fluoride, and 20 mM β-glycerolphosphate. 5x Laemmli sample buffer was added to a final concentration of 1x and lysates were boiled for 6 minutes as well as ground for 15 s using a pestle homogenizer. The resulting lysates were subjected to SDS-PAGE and western blotting. Proteins were detected using anti-HSF1 antibody (Thermo Fisher, Cat\# PA3-017, diluted 1:1000) or anti-Actin antibody (Millipore, Cat\# MAB1501, diluted 1:1000) in TBST containing 5% (w/v) milk powder.

### mRNA isolation, library construction, and high-throughput sequencing {#sec4.4.21}

Approximately 100 worms were collected by hand, washed with M9 buffer, and immediately frozen in liquid nitrogen. Total RNA was extracted using Trizol and a Direct-zol RNA MiniPrep kit (Zymo Research). mRNA-seq libraries were constructed using a TruSeq RNA SamplePrep V2 kit (Illumina). Multiplexed single-end sequencing of mRNA-seq libraries was conducted for 50 cycles on an Illumina HiSeq 3000 according to the manufacturer's instructions. Image analysis, base calling and quality scoring were performed in real time with the standard Illumina analysis pipeline using a phiX control.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For the automated lifespan and heat stress assays, survival data from the 'lifespan machine' was assessed using the 'Survival' package in R ([@bib97]). For manual lifespan assays, survival data was analyzed using OASIS2 ([@bib36]). In both cases, Kaplan-Meier estimated survival curves were compared to each other using the log-rank test. For the maximum velocity and thrashing healthspan assays, velocity and body bends were measured using the ImageJ plugin 'wrMTrck' ([@bib69]) and Microsoft Excel, and population distributions were assessed using the Wilcoxon-Mann-Whitney test from the preinstalled 'wilcox.test' function in R. The exact number of animals used for each assay and further statistic details are indicated in the Supplementary Tables. For western blot quantification we used ImageJ. Statistical significance in western blot and dauer formation experiments was determined by two-tailed unpaired t test using GraphPad Prism 7.05. For all comparisons and assays, statistical significance was defined as p \> 0.05.

### Analysis of the mRNA-seq data {#sec4.5.1}

Reads were aligned to the *C. elegans* genome using the TopHat (v2.0.8b) software package ([@bib99]), known gene model annotations (WS235), and the following parameters: \--library-type fr-unstranded \--b2-very-sensitive \--min-coverage-intron 10 \--min-segment-intron 10 \--microexon-search \--no-novel-juncs. Transcript abundance (FPKM, fragments per kilobase of transcript per million fragments) and differential expression were calculated using Cuffdiff (v2.1.1) included in the Cufflinks software package ([@bib100]) using the following parameters: -u \--FDR 0.05 \--upper-quartile-norm \--compatible-hits-norm \--library-type fr-unstranded. All conditions were analyzed at least in biological duplicate. Replicates were individually mapped and then combined by Cuffdiff. All analyses were limited to protein-coding genes. Statistically significant differentially expressed genes (DEGs) were identified using a 5% FDR. Differential gene expression values were calculated as the ratio of FPKM values.

Data and Software Availability {#sec4.6}
------------------------------

The high-throughput sequencing data generated by this study is available at the Sequence Read Archive at NCBI, under the accession number SRA: PRJNA523315. The R script to make geroprotective predictions can be downloaded at the following link: <http://riedellab.org/downloads/GeroprotectorPredictor.7z>
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